Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 8/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 8/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.71 |
| ▸ | HTR1D | P28221 | 4/20 | 0.71 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.71 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.71 |
| ▸ | HTR1B | P28222 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | BLM | P54132 | 3/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | HRH2 | P25021 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11608848 | 0.98 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| SCHEMBL11180812 | 0.86 | ADRA2A (0.76) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| SCHEMBL11761437 | 0.83 | ADRA2C (0.71) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| Pi-Clonidine SCHEMBL563884 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| Apraclonidine SCHEMBL34128 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| Apraclonidine SCHEMBL1002875 | 0.82 | BLM (1.00) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| Apraclonidine SCHEMBL1649431 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| Pi-Clonidine SCHEMBL5274141 | 0.82 | LMNA (1.00) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| SCHEMBL6844110 | 0.80 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CADRA1AHTR1D | |
| Clonidine SCHEMBL5983 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007638-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | AZURITY PHARMACEUTICALS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12440474-B2 | Stable pharmaceutical compositions of clonidine | AZURITY PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250152558-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | SLAYBACK PHARMA LLC (US) | 2025-05-15 | — | — | US | disclosed |
| US-12233049-B2 | Stable pharmaceutical compositions of clonidine | SLAYBACK PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20230149359-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | AZURITY PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149359-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | AZURITY PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-4897412-A | Imidazolines useful in lowering intraocular pressure | LABORATORIES ALCON S.A. (FR) | 1990-01-30 | — | — | US | disclosed |
| US-4801617-A | Iminoimidazolidines useful in lowering intraocular pressure | LABORATOIRES ALCON, S.A., 68240 KAYERSBERG, FRANCE, A CORP. OF FRANCE | 1989-01-31 | — | — | US | disclosed |
| WO-1988007995-A2 | COMPOUNDS POSSESSING BETA-ANTAGONISTIC AND ALPHA-ANTAGONISTIC PROERTIES, SUITABLE FOR LOWERING THE INTRAORBITAL PRESSURE, PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS, UTILIZATION THEREOF | LABORATOIRES ALCON S.A. (FR) | 1988-10-20 | — | — | WO | disclosed |
| US-4094964-A | IMMUNOASSAY, HAPTEN, ANTIGEN | HOFFMANN-LA ROCHE INC. (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440474-B2 | Stable pharmaceutical compositions of clonidine | ADRA2C, SLC6A2, ADRA2A | ADRA2A 3/4885ADRA2B 10/4885ADRA2C 1/4885 |
| US-12233049-B2 | Stable pharmaceutical compositions of clonidine | ADRA2C, SLC6A2, ADRA2A | ADRA2A 3/4885ADRA2B 10/4885ADRA2C 1/4885 |
| US-20260007638-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | CHRM2, GLP1R, CHRM1 | ADRA2A 58/4885ADRA2B 25/4885ADRA2C 26/4885 |
| US-20250152558-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | ADRA2C, SLC6A2, ADRA2A | ADRA2A 3/4885ADRA2B 10/4885ADRA2C 1/4885 |
| US-20230149359-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINE | ADRA2C, SLC6A2, ADRA2A | ADRA2A 3/4885ADRA2B 9/4885ADRA2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.